Radiation Therapy for Brain Cancer

(INSIGHT MRL Trial)

This trial tests a new radiation therapy approach for individuals with high-grade glioma, an aggressive brain cancer. Researchers aim to determine if Hypofractionated Radiation Therapy, combined with the drug Temozolomide, is safe and tolerable for patients. Ideal participants have a diagnosis of Grade 3 or 4 glioma, have undergone surgery, and can receive MR-Linac radiation therapy. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that hypofractionated radiation therapy, which involves administering larger doses of radiation over a shorter period, is generally safe for treating brain cancer, such as high-grade glioma. One study with 127 patients found no major differences in survival rates with this method. Another study found that combining this therapy with Temozolomide, a chemotherapy drug, was both safe and effective.

Temozolomide is a common treatment for brain tumors and is usually well-tolerated. However, some patients might experience side effects like low blood cell counts, which are typically manageable. A study found that treatment breaks were not more common with the standard dose used in trials, suggesting that most patients can handle the treatment well.

Unlike the standard treatments for brain cancer, which often rely on conventional radiation therapy and chemotherapy, the study treatment combines Magnetic Resonance (MR)-Linac Radiation Therapy with Temozolomide. This innovative approach uses an MR-Linear Accelerator system for precise radiation delivery, potentially improving targeting accuracy and minimizing damage to healthy brain tissue. Researchers are excited about this treatment because it might enhance the effectiveness of radiation therapy while reducing side effects, offering a new level of precision in treating brain cancer.

Research has shown that hypofractionated radiation therapy, which uses shorter, higher doses, can effectively treat glioblastoma, a type of brain cancer. One study found that patients lived for a median of 12 months, achieving similar survival rates to traditional radiation but in a shorter treatment time. In this trial, participants will receive a combination of MR-Linac Radiation Therapy and temozolomide, a chemotherapy drug. Studies have demonstrated that combining radiation with temozolomide can lead to better outcomes. Specifically, one study found that using both radiation and temozolomide more than doubled the two-year survival rate compared to radiation alone. This combination treatment is now a standard approach to improve survival for brain cancer patients.¹⁶⁷⁸⁹